Table 4. ORR at day 28 by baseline... | American Society of Hematology

Table 4.

ORR at day 28 by baseline steroid-refractory status

Response	GVHD progression after 3 d* (n = 19)	No improvement in GVHD after 7 d* (n = 30)	New GVHD† (n = 8)	Taper intolerant (n = 14)
CR	7 (36.8)	6 (20.0)	1 (12.5)	5 (35.7)
VGPR	4 (21.1)	1 (3.3)	1 (12.5)	1 (7.1)
PR	1 (5.3)	7 (23.3)	2 (25.5)	3 (21.4)
Overall response	12 (63.2)	14 (46.7)	4 (50.0)	9 (64.3)
95% CI	38.4-83.7	28.3-65.7	15.7-84.3	35.1-87.2

Response	GVHD progression after 3 d* (n = 19)	No improvement in GVHD after 7 d* (n = 30)	New GVHD† (n = 8)	Taper intolerant (n = 14)
CR	7 (36.8)	6 (20.0)	1 (12.5)	5 (35.7)
VGPR	4 (21.1)	1 (3.3)	1 (12.5)	1 (7.1)
PR	1 (5.3)	7 (23.3)	2 (25.5)	3 (21.4)
Overall response	12 (63.2)	14 (46.7)	4 (50.0)	9 (64.3)
95% CI	38.4-83.7	28.3-65.7	15.7-84.3	35.1-87.2

Data are presented as n (%).

After primary treatment with methylprednisolone at least 2 mg/kg per day.

In another organ in patients who previously received corticosteroids (≥1 mg/kg per day methylprednisolone) for skin or skin plus upper GI GVHD.